Management issues in COPD
=========================

Lung function, dyspnoea and quality of life
-------------------------------------------

Chronic obstructive pulmonary disease (COPD) is a condition defined as a disease state characterized by airflow limitation that is not fully reversible. The airflow limitation is usually progressive and is associated with an abnormal inflammatory response of lungs to noxious particles or gases, primarily caused by cigarette smoking ([@b17-copd-1-425]). In Europe, COPD is ranked as the third most common cause of death ([@b70-copd-1-425]).

The lung function and consequently patient quality of life worsens as disease progresses ([@b82-copd-1-425]; [@b42-copd-1-425]). The standard way of assessing the progression of COPD ([@b15-copd-1-425]) is an annual decline in forced expiratory volume in one second (FEV~1~), which is considered to be the best single correlate of mortality ([@b17-copd-1-425]) and is used as the main parameter in the evaluation of many other COPD aspects. In comparison with the normal subject where the FEV~1~ decline reaches 20--30 mL/year, in COPD patients it reaches 60 mL/year ([@b2-copd-1-425]). This accelerated decline in lung function is closely associated with an increased number of neutrophils in the sputum ([@b88-copd-1-425]) and hence with higher level of airway inflammation. This, on the other hand, is proportional to the rise in the colonizing bacterial load as well as its changes ([@b103-copd-1-425]).

Cross-sectional studies have shown that quality of life deteriorates as lung function declines ([@b87-copd-1-425]). Some groups, however, reported that the health status and health-related quality of life (HRQOL) do not strongly correlate with the lung function parameters such as FEV~1~ ([@b3-copd-1-425]), but relate more to exercise performance, mobility, and mortality ([@b48-copd-1-425]; [@b32-copd-1-425]). Since any improvement in physical performance relates to an improvement in quality of life scores and dyspnoea perception ([@b100-copd-1-425]), the limitation of a functional status is considered very highly predictive of survival (ZuWallack et al 2004). Furthermore, dyspnoea correlates more closely with an impact on HRQOL than FEV~1~. Therefore, dyspnoea and HRQOL have become an important focus for therapy as dyspnoea is the predominant complaint for which patients with COPD seek medical attention ([@b40-copd-1-425]).

Exacerbations
-------------

Patients with COPD are prone to periodic acute exacerbations (AE) of their disease with worsening of the respiratory symptoms and inflammatory parameters ([@b30-copd-1-425]). The frequency of these exacerbations varies, depending on the definition and severity ([@b102-copd-1-425]). AE contributes to a diminished HRQOL and consequently to the reduced health status, frequent hospitalizations, and eventually increased morbidity ([@b29-copd-1-425]). Moreover, the exacerbations lead to the increased healthcare costs with exacerbations associated with a hospitalization accounting for 90% of the total costs of exacerbations ([@b67-copd-1-425]).

Furthermore, the number of exacerbations per year correlates with disease severity ([@b84-copd-1-425]). An increased frequency of these episodes may hasten disease progression and accelerate the decline in the lung function since a physiologic recovery after an exacerbation is usually incomplete resulting in the decrease in quality of life and a tendency to future exacerbations ([@b29-copd-1-425]). Also more pronounced physiologic changes during AE are related to a longer exacerbation recovery time. Additionally, it has been reported that lung function together with health status are the most important risk factors for the re-admission that also relate to the psychological status of the patients ([@b39-copd-1-425]). Therefore the prevention of an acute exacerbation and improving the health status should be considered as one of the most important therapeutic targets.

Oxidative stress and inflammation
---------------------------------

There is increasing evidence that an oxidant/antioxidant imbalance, in favor of oxidants, occurs in COPD ([@b75-copd-1-425]; [@b58-copd-1-425]). The main reason for this is cigarette smoke which is a complex mixture of more than 4700 chemical compounds, including high concentrations of free radicals and other oxidants ([@b18-copd-1-425]). Components of the lung matrix (eg, collagen, elastin) can be directly damaged by the cigarette smoke ([@b16-copd-1-425]). In the breath, the oxidants generated by cigarette smoking or released from leukocytes and epithelial cells, are increased in stable patients and those with an acute exacerbation of COPD ([@b27-copd-1-425]; [@b61-copd-1-425]). There is also evidence that a systemic oxidative stress is present in the COPD patients. This is reflected by an increased production of superoxide anion from the peripheral blood neutrophils in stable ([@b66-copd-1-425]) and exacerbated COPD patients ([@b75-copd-1-425]). Oxidative stress is inextricably linked to the inflammatory response. It becomes clear that the inflammatory process potentiates as COPD progresses ([@b42-copd-1-425]) and exerts damage which is irreversible. This damage involves a complex remodeling process resulting in emphysema and fibrosis of the small airways. Tobacco smoking is not only a major source of the oxidants but is also a major factor initiating the local inflammatory response ([@b19-copd-1-425]).

During acute exacerbation of COPD (AE), except for changes in the overall health status, there are differences observed in the inflammatory and oxidative stress status of the patients. The increased number of inflammatory cells and the accompanying elevated cytokine levels in stable COPD patients tend to rise even further during AE ([@b30-copd-1-425]), reflecting the worsening of the underlying chronic inflammation in the lungs. These acute-upon-chronic episodes augment the damage exerted by chronic processes and may diminish the chances of full recovery.

The management points in COPD are shown in [Figure 1](#f1-copd-1-425){ref-type="fig"}.

Role of mucolytics
==================

For patients suffering from COPD, asthma, and cystic fibrosis, mucus hypersecretion is considered to be a risk factor for increased morbidity. While chronic mucus hypersecretion may not impair the lung function of the healthy individual, in a case of obstructive lung disorder, excessive mucus production accompanied by an inadequate mucus clearance may further hinder the air passage by clogging the already obstructed airways ([@b47-copd-1-425]). The mucus is a complex mixture of proteins, lipids, water, and electrolytes ([@b85-copd-1-425]; [@b78-copd-1-425]) that, under normal conditions, maintains the moisture of the airway epithelium. It is produced by goblet, mucous, and serous cells ([@b57-copd-1-425]) and stored until a secretory signal is given. The mucus secretion may be stimulated by mediators produced by macrophages, lymphocytes, and epithelium ([@b20-copd-1-425]; [@b36-copd-1-425]). Furthermore, in the view that neutrophils are the key cells in COPD, there is emerging evidence that they play a key role in epidermal growth factor receptor (EGFR)-mediated mucin production through releasing tumor necrosis factor-alpha (TNF-α) and hence inducing EGFR expression ([@b91-copd-1-425]; [@b51-copd-1-425]). Moreover, the differentiation of the mucus cells as well as secretion of the mucus from airway glands are induced by neutrophil elastase ([@b13-copd-1-425]).

Nevertheless, by entrapping and removing foreign materials, the mucus forms a basic defense system of the respiratory system. In the large airways, mucus hypersecretion causes coughing and sputum production. In the peripheral airways, because of the smaller diameter, the formed mucus plugs are difficult to remove and may block the peripheral airway completely. This, in turn, may result in gas trapping with increased total lung capacity (TLC) and decreased forced vital capacity (FVC). In COPD, mucus hypersecretion is associated with disease exacerbation ([@b73-copd-1-425]), accelerated decline in FEV~1~ ([@b101-copd-1-425]) and inflammatory cell infiltration ([@b102-copd-1-425]). Moreover, the remaining sputum hinders the accessibility of inhaled medication to the peripheral airways. Therefore the mucus clearance and sterility maintenance are of importance in COPD. There is a large number of medications available that are meant to change the properties of airway secretion or block its production or release, or both. The mucolytics are responsible for the disruption of the mucous gel, generally by altering the degree of the cross-linking or the interactions between molecules in the gel. They include N-acetylcysteine (NAC) and related compounds, dornase--α, F-actin de-polymerizing agents and nondestructive mucolytics, like hypertonic saline and oligosaccharide agents and were previously reviewed ([@b52-copd-1-425]).

Current treatments for COPD are symptomatic and focus on the bronchodilatation. No effective medication currently exists that may influence the progress of the disease. Therefore, mucolytics like NAC may form an interesting therapeutic approach. Classical mucolytics, like NAC and other thiol reducing agents, degrade the three-dimensional network that forms the mucus by reducing the disulphide bonds (S-S) to a sulfhydryl (SH) bond (-SH) that no longer participates in the cross-linking. They may act on the mucus elasticity and viscosity as well as modulate its production and secretion ([@b56-copd-1-425]; [@b52-copd-1-425]). NAC has been reported to reduce the viscosity of sputum in both cystic fibrosis and COPD, facilitating the removal of pulmonary secretions ([@b99-copd-1-425]). Moreover, by maintaining the airway clearance, it prevents bacterial stimulation of mucin production and hence mucus hypersecretion ([@b1-copd-1-425]).

NAC however, has also its disadvantages concerning its accessibility of the peripheral airways and risk of bronchospasm in hyperreactive patients. Nevertheless, the superiority of NAC over the other mucolytics may be in its anti-inflammatory and antioxidant properties and its mucolytic actions.

NAC: pharmacology and pharmacokinetics
======================================

N-acetylcysteine is a thiol compound which has a chemical formula C~5~H~9~NO~3~S and a molecular weight of 163.2. It is rapidly absorbed following an oral dose of 600 mg with a peak of 4.6 μM after 60 min ([@b94-copd-1-425]). The plasma half-life has been reported to be 2.5 hours and no NAC is detectable 10--12 hours after administration ([@b25-copd-1-425]). It has been estimated that the oral bioavailability of the intact NAC molecule was about 10% ([@b12-copd-1-425]). Following an oral dose, the majority of NAC is metabolized into another compound since accompanying increase in nonprotein and protein SH groups were found in plasma ([@b21-copd-1-425]; [@b25-copd-1-425]). Normalized maximal plasma concentration was reported to be significantly higher after a 600 mg dose than after a 200 mg dose. Moreover, increasing the dose also increased NAC bioavailability and time for maximal plasma concentration ([@b12-copd-1-425]). Yet, higher concentration in plasma may be achieved after the intravenous administration ([@b74-copd-1-425]; [@b23-copd-1-425]). During absorption, NAC is rapidly metabolized to cysteine, whose thiol group has reducing and antioxidant properties and which is a direct precursor of the glutathione. Because of its ability to reduce disulphide bounds, NAC is widely used to reduce viscosity and elasticity of the mucus ([@b6-copd-1-425]). Moreover, NAC has the potential to interact directly with oxidants such as hydrogen peroxide, hydroxyl radical, and hypochloric acid ([@b6-copd-1-425]). To exert some effects in the lungs, concentration of NAC or its derivatives have to be sufficiently elevated in bronchial epithelium or in epithelial lining fluid. Nevertheless, no NAC was found in bronchoalveolar lavage fluid (BALF) after 2 weeks of NAC intake (200 mg three times daily \[tid\]) by healthy volunteers ([@b22-copd-1-425]).

Antioxidant properties
----------------------

As a source of SH groups in cells, NAC can stimulate glutathione (GSH) synthesis and play a role in the detoxification ([@b50-copd-1-425]) and play an important role in the antioxidant defense. However, when administered orally it fails to reach the desired concentration in the lungs as 600 mg/day did not alter cysteine and glutathione in BALF of healthy volunteers. However, it significantly increased free and total plasma glutathione and cysteine ([@b22-copd-1-425]). When 600 mg was administered to COPD patients an increase in plasma cysteine was observed with no difference in GSH levels. The higher dose was necessary (600 mg tid) in order to increase GSH levels in COPD patients ([@b14-copd-1-425]). This observation may suggest that under the condition of permanent oxidative stress, 600 mg may not be sufficient to replenish the diminished GSH content. NAC can also act as direct scavenger of free radicals such as OH and H~2~O~2~ and O~2~ ([@b8-copd-1-425]) and it can protect against O~2~ toxicity in the lung ([@b31-copd-1-425]).

Anti-inflammatory properties
----------------------------

Inflammatory response is strongly influenced by redox-sensitive nuclear transcription factor-κB (NF-κB) which regulates a variety of pro-inflammatory genes, and hence modulates the inflammatory response ([@b28-copd-1-425]). In vitro studies showed that a decrease in several inflammatory mediators was related to NF-κB activity inhibition ([@b55-copd-1-425]). Due to the fact that NAC modulates the cellular redox status, it can affect several pathways leading to decrease in NF-κB activity ([@b44-copd-1-425]). Namely, NAC may affect thioredoxin and glutaredoxin expression which form other parts of ubiquitously expressed thiol-reducing system next to glutathione. Thioredoxin increases DNA binding of NF-κB by reducing cysteine of the p50 subunit ([@b59-copd-1-425]) while glutaredoxin by sensing the changes in the redox state of GSH/GSSG may be involved in altering signal transduction pathways resulting in biological responses modulation ([@b86-copd-1-425]). By decreasing the release of thioredoxin and glutaredoxin, NAC may attenuate NF-κB binding to DNA ([@b43-copd-1-425]; [@b64-copd-1-425]) resulting in an impaired inflammatory response ([@b72-copd-1-425]). Except from its effects on transcription factor NF-κB, NAC influences several signaling pathways such as p38, ERK1/2, SAPK/JNK, c-Jun, and c-Fos, among others ([@b105-copd-1-425]). Clinical application of NAC in different disorders as well as its molecular actions have been reviewed previously ([@b105-copd-1-425]; [@b106-copd-1-425]).

Role of NAC in COPD
===================

Lung function
-------------

N-acetylcysteine was reported to improve the lung function when administered for a longer period of time. Namely, [@b71-copd-1-425] reported a significant improvement in FEV~1~ and maximal expiratory flow at 50% of forced vital capacity (MEF~50~) after 6 month treatment of stable COPD patients with NAC (600 mg/day). It supported the study of [@b7-copd-1-425] who observed an improvement from 25 to 30% FEV~1~ (% predicted) in the NAC-treated group during the 4 weeks study period ([@b7-copd-1-425]). On the other hand, several groups did not find any changes in FEV~1~ and FVC although some reduction of hyperinflation was obtained ([@b26-copd-1-425]; [@b97-copd-1-425]).

Exacerbation
------------

As far as exacerbations are concerned, in a recent literature review, [@b73-copd-1-425] found that regular use of mucolytics resulted in a significant reduction of exacerbations by 0.07 exacerbation/month and reduction of illness days of 0.56 days/month. Moreover, the study of [@b34-copd-1-425] found the correlation between the dose of NAC and the number of hospitalizations due to exacerbation. They concluded that NAC may decrease the risk of hospitalizations by about 30%. This reduction however needed minimal dose of 400 mg/day in order to reach protective effect ([@b34-copd-1-425]). It was also supported by study of [@b11-copd-1-425], who showed a reduction in exacerbation rate of 40%, which was significantly different from 19% in placebo group. On the other hand, some studies only observed a trend towards a lower exacerbation rate ([@b68-copd-1-425]) or no effect at all ([@b76-copd-1-425]). Nevertheless, those studies reported a significant reduction in a sick-leave days after 4 and 6 months of NAC treatment. The last large, 3-year study on NAC, the BRONCHUS trial, reported a significant decrease in exacerbation rate only with no concomitant steroid therapy ([@b26-copd-1-425]). The reports on NAC as add-on treatment during an acute exacerbation of COPD are scarce. The study of Black et al showed that the treatment of AE with NAC (600 mg twice daily) did not affect breathlessness, lung function, and oxygen saturation ([@b10-copd-1-425]).

The mechanisms underlying the reduction in the number of exacerbations as well as the days of illness are not very well described. Because of the fact that no significant increase in GSH level was found in plasma and BALF while using low dose (600 mg daily) higher dosages were necessary (600 mg tid) to obtain sustained effect on the thiols level in plasma, it seems unlikely that the changes induced by lower dose of NAC may alter the exacerbation rate or the course of exacerbations. On the other hand, NAC was reported to influence sputum cytokine level ([@b97-copd-1-425]) as well as sputum chemoattractant properties ([@b98-copd-1-425]). Because of the fact that a correlation between exacerbation frequency and sputum IL-6 and IL-8 levels exists ([@b9-copd-1-425]), NAC, by acting on baseline level of those cytokines, may play a role in limiting the inflammatory status and hence modulate the exacerbation frequency. Moreover, by decreasing the viscosity of the sputum, it may facilitate the airway clearance and hence influence the course of the exacerbation, since there is a relationship between bacterial colonization and exacerbation frequency and character ([@b69-copd-1-425]). Effects of NAC on lung function and exacerbation rate are summarized in [Table 1](#t1-copd-1-425){ref-type="table"}. The results from aforementioned reports indicate that low doses of NAC may have rather low antioxidant potential resulting in insignificant improvement of the lung function and limited influence on the exacerbation rate.

Inflammation and oxidative stress in COPD
-----------------------------------------

N-acetylcysteine has been reported to influence several factors that are involved in the modulation of the inflammatory response. Namely, NAC decreased the chemoattractant properties of the sputum of COPD patients after 10 month treatment ([@b98-copd-1-425]) and modulated the inflammatory response after 10 weeks of intake ([@b81-copd-1-425]). Moreover, in healthy volunteers it decreased the formyl-methionyl-leucyl-phenylalanine (fMLP)-stimulated respiratory burst and chemotaxis ([@b80-copd-1-425]). Furthermore, in the study of [@b95-copd-1-425], NAC improved the phagocytotic ability of neutrophils while decreasing their production of superoxide anion (SA) with no effects on migration already after 14 days of administration in healthy volunteers.

As far as oxidative stress is concerned, NAC decreased the exhaled H~2~O~2~ levels in COPD patients after long-term treatment ([@b49-copd-1-425]; [@b24-copd-1-425]). Moreover, when administered to healthy volunteers, it increased the glutathione peroxidase activity (GPx) after 2 weeks of oral treatment ([@b95-copd-1-425]) and increased thiol level after 30 min and 3 hours after administration ([@b90-copd-1-425]).

It did not, however, influence GSH and cysteine level in BALF and lung tissue ([@b14-copd-1-425]).

Furthermore supplementation with NAC (200 mg × 4/day for 2 days + 800 mg on the test morning) increased the pre-exercise scavenging activity of healthy volunteer plasma ([@b83-copd-1-425]). When administered in higher doses (125 mg/kg) (intravenously) NAC significantly increased GSH content and attenuated its decline during intense intermittent exercise and led to lesser glutathione disulfide (GSSG) formation ([@b63-copd-1-425]).

These reports strongly suggest that for effective anti-inflammatory and antioxidant action, higher doses are necessary as the low NAC concentration (as also observed in vitro) was not found satisfactory ([@b79-copd-1-425]). This could be due to pharmacokinetics of NAC and administration route, which is far from optimal as it is unlikely to achieve desired concentration in the lung compartment ([@b14-copd-1-425]). The novel route (eg, inhalation) is currently under investigation for both NAC and its derivatives and it is discussed in the last section.

Patient-focused perspectives
============================

Quality of life
---------------

FEV~1~ hardly correlates with dyspnoea, which is closely related to the patient's quality of life and which can vary among the patients with the same degree of the airway obstruction ([@b104-copd-1-425]). Dyspnoea, on the other hand, may reflect more comprehensive information than airway obstruction in patients with COPD and should be taken into account while evaluating the successful treatment. NAC was reported to decrease the dyspnoea in COPD patients in comparison with placebo during the long-term treatment ([@b7-copd-1-425]; [@b92-copd-1-425]). This may be partly caused by the mucolytic effects of NAC leading to increase in the sputum volume and pourability. Moreover, an improvement in the subjects' clinical state after NAC treatment has been noted ([@b46-copd-1-425]) as well as an improvement of bronchitis-related symptoms ([@b89-copd-1-425]) and increase in the patients' well-being ([@b41-copd-1-425]). Furthermore, in study of [@b71-copd-1-425], 65% of the treated patients reported improvement in quality of life in the NAC group (NAC on top of the current therapy) compared with 29% in placebo group.

As far as the influence of NAC on physical activity is concerned, it successfully improves the performance on fatiguing exercise when administered in high dosages. Namely, in the study by [@b60-copd-1-425], at the oral dose of 150 mg/kg, NAC delayed handgrip fatigue, increasing task performance by one-third compared with the baseline. Similarly, in the study by [@b62-copd-1-425] (125 mg/kg intravenously), NAC increased time to fatigue. Furthermore, the same dose was reported to inhibit fatigue of human skeletal muscles caused by repetitive, low-frequency electrical stimulation ([@b77-copd-1-425]). Moreover, high doses of NAC (600 mg × 3/day) prevented the exercise-induced increase in plasma thiobarbituric reactive substances and O~2~ release and led to improved endurance time ([@b53-copd-1-425]). It may be suggested that NAC in high doses may act on GSH content replenishment and may increase the task performance and have positive effect on the physical activity and hence quality of life.

Compliance
----------

The compliance is concerned to be better following the 600 mg/day regimen ([@b71-copd-1-425]). For example, in the BRONCHUS study, a compliance of 94% in the NAC group was observed in comparison with 92% in the placebo group ([@b26-copd-1-425]). Nevertheless, a lower compliance observed at the regimen of 200 mg tid could be improved, following additional patient instructions ([@b68-copd-1-425]).

Tolerability and side-effects
=============================

NAC is generally safe. The oral dose of 600 mg/day or less is usually very well tolerated with no apparent side-effects and no impact on the patient satisfaction ([@b46-copd-1-425]; [@b68-copd-1-425]; [@b89-copd-1-425]). A dose of 1800 mg/day administered for a period of 4 days in COPD patients ([@b53-copd-1-425]) and for 5--6 weeks in the polycystic ovary syndrome was also well tolerated with no reported side-effects ([@b33-copd-1-425]). Nevertheless, some trials mention some gastro-intestinal adverse reactions, which are not significantly different from placebo group and comprise of dyspepsia, diarrhea or heartburn ([@b7-copd-1-425]). In the last study of [@b60-copd-1-425] where 150 mg/kg of NAC was administered orally, mild reactions were reported in most of the patients (erythema, sweating, altered sensations, gastrointestinal disturbances). Except for gastrointestinal disturbances that persisted up to 4 hours and light-headedness which disappeared after 3 hours, the remaining complaints disappeared 60 min after indigestion of NAC. The most common side-effects associated with high oral doses are nausea, vomiting, and other gastrointestinal disturbances, and therefore oral administration is contraindicated in persons with active peptic ulcer ([@b54-copd-1-425]). On the other hand, at low doses NAC may have a positive influence on the bacterial colonization in gastritis ([@b45-copd-1-425]). Infrequently, anaphylactic reactions after intravenous administration due to histamine release occur and can consist of rash, angioedema, bronchospasm, tachycardia, and changes in blood pressure ([@b93-copd-1-425]).

Cost-effectiveness
==================

High prevalence of COPD carries with it serious financial consequences. According to the *Belgisch Instituut voor Gezondheidseconomie,* the costs of COPD increase together with the disease progression amounts to (in €/year/patient) 2977€ for Stage I, 4740€ for Stage II, and 8565€ for Stage III, and IV (De Backer pers comm).

Disease severity, on the other hand, correlates with the number of exacerbations per year ([@b84-copd-1-425]). Since exacerbation is one of the important factors facilitating the progression of the disease and brings additional costs to the global expenditure, which are especially high in case of hospitalization or intensive care unit admission ([@b65-copd-1-425]), effective exacerbation prevention could be the major cost-reducing factor.

Grandjean and colleagues (2000) showed that NAC at dose 400 mg/day not only led to a significant reduction in the number of exacerbations but also resulted in a smaller percentage of sick-leave days and lower hospitalization rate, what leads to a direct (NAC treatment, AE management, hospitalization) and indirect (sick-leave days) cost reduction.

Conclusion: optimal usage, place in therapy, and future perspectives
====================================================================

Based on the accessible literature, NAC in COPD has been studied mostly at rather low dosages with variable outcomes. The short-term, low-dose studies suggest that NAC may not be a drug of choice to enhance the GSH antioxidant potential of the lungs, since the effects are poor. While its effect on the oxidative stress markers seems to be influenced even at low dosages, the higher doses may ensure more rapid response. On the other hand, even long-term administration at low doses does not always have the anti-inflammatory potential but substantially higher doses are necessary as in vitro studies have already demonstrated. As far as exacerbation rate, the number of sick-leave days and quality of life are concerned; the use of NAC seems to be promising as the majority of studies give favorable reports even at 600 mg/day dose.

Because of the fact that higher doses seem to be more effective in inflammation and oxidative stress modulation with little side-effects, a change in the administration pattern may be of importance.

Furthermore, evaluating novel methods of drug delivery (inhaled NAC) ([@b90-copd-1-425]) and use of NAC derivatives with better bioavailability may result in more effective treatment. For example, Nacystelyn (NAL), a lysine salt of NAC, has mucolytic and antioxidant properties. Its mucolytic activity is approximately equal to the sum of the activities of its two components, namely acetylcysteine and lysine, and its antioxidant properties are comparable with those of NAC ([@b96-copd-1-425]). Moreover, because of its neutral pH, NAC can be delivered into the airways in inhaled form ([@b35-copd-1-425]; [@b4-copd-1-425]). The inhaled form, tested in cystic fibrosis patients, was well tolerated and positively influenced airway mucus clearance ([@b5-copd-1-425]).

Another, newly developed form of NAC is N-acetylcysteine amide (NACA). Because of its neutral carboxyl group, NACA is lipophilic, cell permeating and has strong antioxidant and protective effects ([@b38-copd-1-425]). Nevertheless, more studies are necessary to assess the effectiveness of those derivatives in lung disorders in vivo.
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###### 

Effects of NAC on clinical COPD outcomes

                                                           Dose      Number   Study period   FEV~1~   QOL                             Dyspnea   Exacerbation                                   Hospitalisation/sick days   Side effects                                    Ref
  -------------------------------------------------------- --------- -------- -------------- -------- ------------------------------- --------- ---------------------------------------------- --------------------------- ----------------------------------------------- -----
  **400 mg**                                               200 × 2   259      6 months       --       --                              --        ⇓                                              ⇓                           NO                                              12
  **600 mg**                                               600 × 1   248      2 months       --       --                              ⇓         --                                             --                          23%[x](#tfn3-copd-1-425){ref-type="table-fn"}   93
                                                           600 × 1   523      3 years        NS       NS                              --        ⇓[\#](#tfn2-copd-1-425){ref-type="table-fn"}   --                          NO                                              29
                                                           600 × 1   169      6 months                Improvement in cough severity   --        ⇓                                              ⇓                           NS                                              73
                                                           600 × 1   20       10 weeks       NS       --                              --        --                                             --                          NO                                              97
                                                           300 × 2   116      6 months       --       --                              --        ⇓ (NS)                                         ⇓                           NO                                              79
                                                           200 × 3   180      5 months       --       --                              --        ⇓ (NS)                                                                     NS                                              1
                                                           200 × 3   526      6 months       --       --                              --        NS                                             ⇓                           Well-tolerated                                  70
                                                           200 × 3   121      3 months       --       --                              --        --                                             --                          Well-tolerated                                  48
  **1200 mg**                                              600 × 2   153      22 weeks       NS       NS                              --        ⇓ (NS)                                         --                          NO                                              43
  [\*](#tfn1-copd-1-425){ref-type="table-fn"}**1800 mg**   600 × 3   9        4 days         --       --                              --        --                                             --                          NO                                              55

**Note:** short duration COPD;

subgroup without ICS;

percentage of patients suffering from side effects.

**Abbreviations:** COPD, chronic obstructive pulmonary disease; FEV~1~, forced expiratory volume in one second; ICS, inhaled corticosteroid; NAC, N-acetylcysteine; NO, no reported side effects; NS not significantly different from placebo group--not reported; QOL, quality of life.
